Background
Methods
Patients
Study design, data collection and processing
Respiratory function tests
Forced vital capacity
Peak cough flow
Maximum inspiratory and expiratory pressure
Sniff nasal inspiratory pressure
Referral process of patients with ALS to home ventilation services
Data and statistical analysis
Results
All patients (n = 110) | |
---|---|
Demographic and disease variables | |
Male (%) | 60.3 |
Diagnosis ALS/PMA (% ALS) | 84.0 |
Onset spinal/bulbar/both (%) | 60.3 / 23.7 / 16.0 |
Age at referral (years) | 61.5 ± 12.0 |
Disease duration (years)° | 2.0 ± 1.7 |
Mortality (n)° | 67 |
Variables at first evaluation at the HVS | |
Interval referral and first HVS assessment (weeks) | 5.6 ± 5.1 |
PCO2 (mmHg) | 39.4 ± 5.6 |
Bicarbonate (mmol/L) | 26.40 ± 3.69 |
Follow up until NIV (months)* | 9 ± 8 |
Decline in respiratory function
Cut off values
Suggested values | ||||||
---|---|---|---|---|---|---|
Cut-off value | Sensitivity | Specificity | Cut-off value | Sensitivity | Specificity | |
FVC | 95 (77–104) | 85 | 22 | 70 | 65 | 50 |
PCF | 386 (356–472) | 88 | 36 | 300 | 33 | 67 |
MIP | 67 (52–74) | 85 | 27 | 60 | 82 | 35 |
MEP | 74 (66–90) | 85 | 38 | 60 | 68 | 56 |
SNIP | 45 (41–59) | 87 | 40 | 40 | 71 | 50 |
Respiratory function tests at the first HVS assessment
All patients (n = 57) | No NIV indication (n = 35, 61.4%) | NIV indication (n = 22, 38.6%) |
P-value | |
---|---|---|---|---|
Demographic and disease variables | ||||
Male (%) | 50.9 | 54.3 | 45.5 | 0.516 |
Diagnosis ALS/PMA (% ALS) | 87.7 | 88.6 | 86.4 | 0.805 |
Onset Spinal/Bulbar/Both (%) | 45.6 / 36.8 / 17.5 | 40.0 / 37.1 / 22.9 | 54.5 / 36.4 / 9.1 | 0.352 |
Age at referral (years) | 64.6 ± 12.7 | 61.4 ± 13.1 | 69.8 ± 10.3 | 0.014 |
Disease duration (years) | 1.9 ± 1.6 | 2.0 ± 1.6 | 1.8 ± 1.8 | 0.572 |
Deceased (n) | 34 | 19 | 15 | 0.298 |
Variables at HVS | ||||
Interval referral and first assessment (weeks) | 5.6 ± 5.1 | 6.6 ± 5.9 | 4.1 ± 2.9 | 0.056 |
pCO2 at first evaluation (mmHg) | 40.6 ± 6.3 | 37.92 ± 3.19 | 44.95 ± 7.70 | <0.0001 |
Bicarbonate at first evaluation (mmol/L) | 26.7 ± 3.7 | 25.08 ± 2.51 | 29.23 ± 3.88 | <0.0001 |
Follow up until NIV (months)* | 12 ± 6 | 12 ± 6 | 0 ± 0 | - |
No NIV indication yet (n = 35) | NIV indication (n = 22) | |||||
---|---|---|---|---|---|---|
N | N | Difference (SE) |
P-value | |||
FVC | 32 | 79 ± 21 | 20 | 70 ± 20 | −9.9 ± 6 | 0.101 |
PCF | 24 | 348 ± 137 | 16 | 259 ± 92 | −88.4 ± 39 | 0.019 |
MIP | 28 | 59 ± 36 | 19 | 50 ± 26 | −8.9 ± 9 | 0.338 |
MEP | 29 | 46 ± 23 | 18 | 44 ± 21 | −1.9 ± 7 | 0.774 |
SNIP | 15 | 40 ± 18 | 5 | 28 ± 9 | −12 ± 12 | 0.089 |
Complaints | 35 | 51% | 22 | 77% | 0.051 |